Drug Trial Radar · NCT04357366
suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)
Last checked: Nov 20, 2026Latest source record: Jul 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Apr 15, 2020
Primary completion
Jan 29, 2022
Study completion Apr 15, 2022
Sponsor
- Lead sponsor
- Hellenic Institute for the Study of SepsisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the SAVE study patients with lower respiratory tract infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at high risk for progression to serious respiratory failure will be detected using the suPAR biomarker. They will begin early treatment with anakinra in the effort to prevent progression in serious respiratory failure.
Conditions
- COVID-19
- Virus Diseases
- Corona Virus Infection
- Lower Respiratory Tract Infection Viral
Interventions
AnakinraDrug
Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The ratio of patients who will develop serious respiratory failure (SRF)Time frame: Visit study day 14
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
2nd Department of Internal Medicine, University General Hospital of Alexandroupolis
Alexandroupoli, Greece
Department of Internal Medicine, I PAMMAKARISTOS Hospital
Athens, Greece
1st Department of InternalMedicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.
Athens, Greece
1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS
Athens, Greece
1st University Department of Internal Medicine, General Hospital of Athens LAIKO
Athens, Greece
1st University Departmentof Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseasesof Athens
Athens, Greece
2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens
Athens, Greece
3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA
Athens, Greece
Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA
Athens, Greece
Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens
Athens, Greece
1st Department of Internal Medicine Amalia Fleming General Hospital
Athens, Greece
1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO
Athens, Greece
1st Department of Internal Medicine, General Hospital of Nea Ionia CONSTANTOPOULIO-PATISION
Athens, Greece
1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO
Athens, Greece
2nd Department of Internal Medicine, 251 Air Force General Hospital
Athens, Greece
2nd Department of Internal Medicine, General Hospital of Eleusis THRIASIO
Athens, Greece
3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S.
Athens, Greece
5th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens
Athens, Greece
Department of Internal Medicine, General Hospital of Athens ELPIS
Athens, Greece
Department of Infectious Diseases, General Hospital of Kerkira
Corfu, Greece
1st Department of Internal Medicine, General University Hospital of Ioannina
Ioannina, Greece
Department of Internal Medicine, General Hospital of Katerini
Katerini, Greece
Department of Internal Medicine, University General Hospital of Larissa
Larissa, Greece
Department of Internal Medicine, General Hospital of Larisa KOUTLIMBANEIO & ΤΡΙΑΝΤΑFΥLLΕΙΟ
Larissa, Greece
Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA
Pátrai, Greece
2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO
Piraeus, Greece
1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki
Thessaloniki, Greece
COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING
Marousi, Athens, Greece
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.